MedTrace Logo

To Evaluate the Effect of Food on the Pharmacokinetics (PK) of AZD0328

NCT00752830 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2008-10-29

No results posted yet for this study

Summary

The purpose of the study is to evaluate the effect of food on the pharmacokinetics of AZD0328 in healthy male volunteers. AZD0328 will be administered as a single oral dose (capsule) during two treatment periods, after food intake or during fasting condition.

Conditions

  • Healthy

Interventions

DRUG

AZD0328

Oral capsule, single dose

Sponsors & Collaborators

Principal Investigators

  • Didier Meulien, MD · AstraZeneca R&D Södertälje, Sweden

  • Gabriella Samuelsson Palmgren, MD · AstraZeneca Clinical Pharmacology Unit, AstraZeneca R&D Lund,Sweden

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00752830 on ClinicalTrials.gov